Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9S51Q)

• Drug Name: DU-6681 Drug Info
• Synonyms: DU-6681a (Na salt); (1R,5S,6S)-2-[6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-6(S)-ylsulfanyl]-6-[1(R)-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 100935628
  TTD Drug ID: DM9S51Q

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial Penicillin binding protein (Bact PBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[3]
Cefazolin	DMPDYFR	Bacteremia	1A73	Approved	[4]
Ceftriaxone	DMCEW64	Acute gonococcal cervicitis		Approved	[5]
Ticarcillin	DM4ME02	Aspiration pneumonia		Approved	[6]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[7]
Meropenem	DM62UHC	Bacterial infection	1A00-1C4Z	Approved	[5]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[8]
Clofarabine	DMCVJ86	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Cephalexin	DMD5JU8	Acute otitis media	AB00	Approved	[10]
Carbenicillin	DMLEDNK	Infection of the upper and lower urinary tract	GC08	Approved	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Penicillin binding protein (Bact PBP)	TTJP4SM	NOUNIPROTAC	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006219)
• [2] Pharmacokinetics and Safety of Ascending Single Doses of DZ-2640, a New Oral Carbapenem Antibiotic, Administered to Healthy Japanese Subjects. Antimicrob Agents Chemother. 2000 March; 44(3): 578-582.
• [3] Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
• [4] Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7.
• [7] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [8] Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32.
• [9] Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
• [10] Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21.
• [11] Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23.